21 July, 2015.
Following the $8 billion merger of Samsung C&T and Cheil Industries last week, Samsung Group is to significantly expand its biopharmaceutical business, the Korean Herald reports.
Samsung BioLogics, based in Songdo, South Korea, is now expected to lead in the group’s plans to target lucrative, emerging sectors and achieve an annual growth rate of 10.2 percent and $52.7 billion in sales by 2020.
Samsung BioLogics is a contract manufacturer for global pharmaceutical companies such as Bristol-Myers Squibb and Roche. It also owns a 90.3 percent stake in Samsung BioEpis, which specializes in producing biosimilars and which last month revealed plans to list on NASDAQ in a bid to reach its target valuation of at least $8 billion and raise funds for the R&D of six new biosimilar drugs.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.